



n-3 Fatty acids and asthma

Aishwarya Kumar^{1,2*}, Sarabjit S. Mastana¹ and Martin R. Lindley¹

¹*Translational Chemical Biology Research Group, Human Cellular and Molecular Genetics Research Laboratory, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough LE11 3TU, UK*

²*Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK*

Abstract

Asthma is one of the most common and prevalent problems worldwide affecting over 300 million individuals. There is some evidence from observational and intervention studies to suggest a beneficial effect of *n*-3 PUFA in inflammatory diseases, specifically asthma. Marine-based *n*-3 PUFA have therefore been proposed as a possible complementary/alternative therapy for asthma. The proposed anti-inflammatory effects of *n*-3 fatty acids may be linked to a change in cell membrane composition. This altered membrane composition following *n*-3 fatty acid supplementation (primarily EPA and DHA) can modify lipid mediator generation via the production of eicosanoids with a reduced inflammatory potential/impact. A recently identified group of lipid mediators derived from EPA including E-series resolvins are proposed to be important in the resolution of inflammation. Reduced inflammation attenuates the severity of asthma including symptoms (dyspnoea) and exerts a bronchodilatory effect. There have been no major health side effects reported with the dietary supplementation of *n*-3 fatty acids or their mediators; consequently supplementing with *n*-3 fatty acids is an attractive non-pharmacological intervention which may benefit asthma.

Key words: Asthma: *n*-3 Fatty acids: Omega-3 fatty acids: Fish oils: Inflammation

Asthma pathophysiology

Asthma is one of the most common and prevalent health problems worldwide affecting over 300 million individuals. Globally asthma affects 1 to 18 % of the population and it is evident that in both developing and developed countries prevalence of asthma increases as communities adopt modern or 'Western' lifestyles, becoming urbanised⁽¹⁾. It has been projected that with urbanisation continuing to increase worldwide, there is likely to be a marked increase in the number of individuals with asthma living within the next two decades⁽²⁾ and it has been estimated that an additional 100 million individuals worldwide could be potentially affected with asthma by 2025^(3,4). Asthma is partly characterised by transient narrowing of the airways^(5,6). Occasionally this transient narrowing of airways can occur during exercise, resulting in the identification of exercise-induced bronchoconstriction (EIB)^(7,8). For patients with EIB a brief period of exercise or increase in ventilation triggers airflow obstruction which typically lasts for 30–90 min in the absence of treatment^(9,10). Clinical focus for asthma therapy has understandably been on the severe disease state; however, a large number of asthmatics have mild to moderate symptoms⁽¹⁰⁾.

Asthma is a heterogeneous disease with respect to immunopathology, clinical phenotype, response to therapy and

natural history. Symptoms can be triggered by a variety of environmental factors and are further exacerbated by the poor adherence to prescribed medication schedules and suboptimal treatment regimens^(11,12). Thus, the clinical spectrum of asthma is highly variable with airway inflammation being a consistent feature. The pattern of inflammation in asthma is associated with airway hyper-responsiveness (AHR) (clinically measured by histamine or methacholine challenge) which leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or early morning. These episodes are generally associated with airflow obstruction (bronchoconstriction) within the lungs that is often reversible either spontaneously or with treatment. In most asthmatics, inflammation is largely restricted to the conducting airways but with an increase in disease severity, the inflammatory infiltrate spreads to the small airways and in some cases adjacent alveoli⁽¹³⁾.

Another feature of asthma is the response to triggers such as exercise and allergic sensitisation; the airways recognise common triggers and in turn generate a Th2-type cytokine response to them. Asthma is also found to involve local epithelial, mesenchymal, vascular and neurological events, which direct the Th2 lymphocytes to the lung. Repeated bouts

Abbreviations: AA; arachidonic acid; AHR, airway hyper-responsiveness; ALA, α -linolenic acid; COX, cyclo-oxygenase; EIB, exercise-induced bronchoconstriction; FeNO, fractional exhaled NO; FEV1, forced expiratory volume in 1 s; LA, linoleic acid; LOX, lipoxigenase; LT, leukotriene; LX, lipoxin; NOS, NO synthase; PD, protectin; PEF, peak expiratory flow; Rv, resolvin.

* **Corresponding author:** Aishwarya Kumar, fax +44 1865 743985, email Aishwarya.kumar@ndph.ox.ac.uk




Fig. 1. Cells and mediators involved in the asthmatic inflammatory response. APC, antigen-presenting cells; LT, leukotriene.

of increased inflammation in asthma may lead to damage to the airway epithelium and subsequent abnormal repair leads to structural changes in the airway walls of asthmatic subjects (collectively referred to as airway remodelling)^(14,15). Fig. 1 illustrates the role of different cells and mediators involved in the asthmatic inflammatory response to a trigger. There is recruitment and activation of leucocytes in response to the trigger. Following activation, the cells work actively to neutralise the antigens, subsequently they repair any damage; finally, the cells are removed with resolution of the inflammatory process^(16,17).

In asthmatics, there is an increased production of a series of cytokines and chemokines such as TNF, IL-4, IL-5, IL-6, IL-8, IL-12 and IL-13^(18–20). There is also a release of arachidonic acid (AA)-derived eicosanoids including prostaglandins and leukotrienes (LT; such as LTC₄, LTD₄ and LTE₄) that are found to be potent vasoconstrictors of human airways; these mediators affect microvascular and bronchial dilation, increase AHR, and have been implicated in the pathogenesis of asthma^(21,22). Furthermore the prostaglandins exert strong effects on airway function and there is increased expression of the inducible form of cyclo-oxygenase (COX-2) in asthmatic airways; however, the inhibition of their synthesis with COX inhibitors, such as aspirin or ibuprofen, may demonstrate some effect in reducing symptoms in some but not all asthmatics⁽²³⁾. PGD₂ is a bronchoconstrictor produced predominantly by mast cells. Deletion of the PGD₂ receptors in mice significantly inhibits inflammatory responses to allergens and inhibits AHR, suggesting that this mediator may be important in asthma^(24,25).

NO is an endogenous regulatory molecule involved in the pathogenesis of asthma. The synthesis of NO in the airways is mediated by a family of enzymes that are collectively called NO

synthases (NOS)^(26,27). The NOS can exist as constitutive isoforms (cNOSs) including endothelial NOS (eNOS) and neural NOS (nNOS) or as an inducible isoform (iNOS)^(28,29). The inducible isoform (iNOS) is found in the epithelium of the bronchial wall, which is the key source for elevated levels of fractional exhaled NO (FeNO) seen in asthmatics. Alveolar concentration of FeNO is usually low except in diseases such as alveolitis⁽³⁰⁾. During an exhalation process, the air from alveolar compartments moves to the bronchial compartment; thus, the NO from the bronchial wall diffuses inside the airway lumen leading to an increase in NO levels in the expired air. Increased concentration of NO is observed when exhalation is slow, as this allows a longer time for the NO to diffuse in the airways^(26,31). Patients with asthma usually exhibit 2- to 3-fold higher levels of NO in expired air compared with healthy adults⁽³²⁾. Healthy adults can exhibit values between 5–35 parts per billion at the standard flow rate of 50 ml/s^(32,33). The elevated levels of NO in expired air in asthmatics are indicative of eosinophilic inflammation; however, a direct pathogenic role of this gas in asthma is yet to be fully established^(34–36).

Diagnosis and classification

Diagnosis of asthma is predominantly determined by measuring symptoms (episodic breathlessness, wheezing, cough and chest tightness), peak expiratory flow (PEF) and other parameters of spirometry^(37,38). Episodic symptoms after allergen exposures, seasonal variability and a positive family history and atopy are useful diagnostic guidelines⁽³⁹⁾. The presentation of asthma can vary from person to person and asthma may be intermittent with mild to severe episodes requiring treatment^(40,41). Asthmatics may experience intermittent symptoms for a period

of a few minutes and in some cases this may be life threatening. Asthma subgroups have been characterised to address the complexities of the disease and for better understanding of the symptoms. A phenotype or subgroup identifies the clinically relevant properties of the disease, but does not show the direct relationship with disease aetiology and pathophysiology^(42,43). Table 1 shows a classification of asthma into main subgroups including early-onset allergic, eosinophilic, aspirin triggered, exercise induced, obesity related and asthma related to airflow obstruction.

The main diagnostic technique for asthma is an assessment of pulmonary function to identify airflow limitation; this method has been used to demonstrate the reversibility of lung function abnormalities. The measurement of pulmonary function is combined with an assessment of symptoms such as dyspnoea and wheezing; together they provide reliable information about the different aspects of asthma control^(37,38,44). Spirometry is the primary method for pulmonary function testing. The most important aspects of spirometry include forced vital capacity (FVC), which is the maximum volume of air an individual can expel from the lungs, during expiration made as forcefully and completely starting from full inspiration. The forced expiratory volume in 1 s (FEV₁) is the maximum volume of expired air volume in the first 1 s of a FVC manoeuvre. PEF is the maximum expiratory flow achieved from a maximum forced expiration, starting from the point of maximal lung inflation, and is recorded using a PEF meter.

EIB is a subgroup of asthma that affects up to 90 % of individuals with asthma^(7,9,45). EIB has also been reported in non-asthmatics including schoolchildren, armed force recruits, and athletes and approximately 10 % of the healthy population show symptoms of EIB at some point during their lives⁽⁴⁵⁾. Based on the wide prevalence of EIB in both asthmatic and healthy populations, EIB is considered a limiting factor for physical activity for a large number of individuals. The observed symptoms of EIB include coughing, wheezing, chest tightness, shortness of breath or excess mucus production following exercise. However; self-reported symptoms are neither reliable nor specific for EIB. Approximately 50 % of elite athletes report symptoms related to EIB with exercise. However, they do not have EIB, while 50 % of those who report no symptoms for EIB will test positive on the exercise challenge test for EIB^(46,47). Thus, it is essential to support the diagnosis of EIB by performing a relevant exercise challenge test⁽⁴⁸⁾. An exercise challenge test involves exercising at increasing intensities until a heart rate response of 85–90 % of estimated maximal is achieved. The exercise challenge test primarily involves recording a post-exercise reduction in FEV₁ of 10 to 15 % of the pre-exercise value. The value for FEV₁ may start falling during exercise, however; the lowest value will usually be measured 5–12 min after the end of the exercise challenge test. The reduction in FEV₁, if severe, is linked to a decrease in oxygen saturation with hyperinflation of the lungs⁽⁹⁾. In adults, a ≥10 % decline in FEV₁ at any time point within 30 min of ceasing exercise is considered a diagnostic of EIB. The decline in FEV₁ is usually maintained over two time points and any unsustained decline may be due to respiratory muscle fatigue and does not indicate EIB^(49,50).

Table 1. Asthma subgroups

| Asthma subgroup | Clinical and physiological features |
|---|---|
| Early-onset allergic | Allergic symptoms and other diseases Markers: specific IgE, Th2 cytokines Sinusitis, less allergic |
| Late-onset eosinophilic | Markers: IL-5, corticosteroid-refractory eosinophilia Severe asthma attacks, rhinorrhoea and nasal congestion Enhanced airway eosinophilia |
| Aspirin-exacerbated respiratory disease Infection induced | FEV ₁ :FVC ratio below the lower limit of normal for age and FEV ₁ < 90 % predicted in a patient taking corticosteroids, after acute administration of a rapid-onset bronchodilator Mild symptoms, intermittent with exercise. Reduction in post-exercise FEV ₁ Markers: Th2 cytokines, mast cell activation, cysteinyl leukotrienes |
| Asthma associated with apparent irreversible airflow limitation | Note: 10 % of healthy population also suffers from exercise-induced symptoms Mainly women are affected; very symptomatic, AHR Poor asthma control, increased bronchodilator response, lower lung function and exacerbations. More common in aspirin-sensitive asthma. Some association with expired NO levels and requires sputum analysis for diagnosis |
| Exercise induced | |
| Obesity-related asthma Eosinophilic asthma | |

FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; AHR, airway hyper-responsiveness.

Current asthma therapies: challenges and scope for non-pharmacological interventions

Despite effective treatments for asthma, there remain high mortality and morbidity which have implications for public health services. Current asthma treatments target inflammation in one of two ways (acute rescue remedies *v.* long-term preventatives). The existing pharmacological therapies together with long- and short-acting β -agonists and corticosteroids have proved effective in asthma management in the majority of patients, but still have issues associated with their use. Tachyphylaxis has complicated the use of β -adrenoreceptor agonists while the known systemic and local side effects of inhaled corticosteroids include osteoporosis and glaucoma^(2,51). LT modifiers block bronchoconstrictor and pro-inflammatory activity of cysteinyl LT within the asthmatic airway, and IgE monoclonal therapy for reduction in IgE have been found to be effective in asthma treatment^(52,53). There is a current focus on identifying specific therapies that target a single inflammatory mediator and are less likely to have major health side effects⁽⁵¹⁾. These specific therapies have been suggested to be effective for various subgroups of asthma including those with mild-moderate symptoms including EIB. For particularly EIB, inhaled corticosteroids have been identified as the most effective anti-inflammatory treatment available, aiming at reducing AHR and reducing the severity of symptoms. However, inhaled corticosteroids demonstrate both systemic and local health side effects, which affect the sports/physical activity of individuals. Adrenal suppression at high doses, growth retardation in children and adolescents and reduction in bone density are observed with usage of some inhaled corticosteroids^(54,55). The other anti-inflammatory treatments for EIB include LT antagonists, disodium cromoglycate, nedocromil sodium, β_2 -agonists, and ipratropium bromide which have well-established, long-term negative health side effects providing an impetus for non-pharmacological therapies among researchers and clinical experts⁽⁵⁶⁻⁵⁸⁾.

In the UK, the National Health Service and Asthma UK have suggested the use of complementary therapies alongside conventional medication in asthma^(59,60). Consequently, there are both therapeutic and consumer-derived interests in identifying potential complementary therapies for asthma. The recognition of the role of complementary therapy in asthma is limited because these approaches have been insufficiently researched and their effectiveness is largely unproven⁽²⁾. A range of non-pharmacological treatments including physical activity (incorporating a warm-up before and a cool-down period following exercise), performing nasal breathing, avoiding cold weather or environmental allergens, using a face mask or other aid to warm and humidify inhaled air, and modifying dietary intake of *n*-3 fatty acids, salt and antioxidants have been identified⁽⁶¹⁾. However, to date the efficacies of each of these therapies have not been well established and further investigations are required to validate these therapies with conventional standards⁽⁶¹⁾.

Exploring the potential of non-pharmacological treatments is important due to the comparatively low risk associated with their use. Since physical activity is a limiting factor for EIB-prone

individuals, a change in lifestyle and diet could improve the quality of life of these individuals and help them meet the physical activity requirements proposed by the Department of Health. The present review will discuss the mechanisms underlying the effects of *n*-3 fatty acids and the relationship between *n*-3 fatty acids, their derived mediators and respiratory health in asthmatics.

n-3 Fatty acids: structure and metabolism

Fatty acids, both non-esterified and as part of complex lipids, play an important role in metabolism, storage and transport of energy, gene regulation⁽⁶²⁾ and as necessary components of all cell membranes and have been found to be linked to various diseases⁽⁶³⁻⁶⁶⁾. The characteristics of a fatty acid are dependent on the length of carbon chain and the presence, absence and placement of double bonds between carbon atoms. PUFA have more than one double bond present. PUFA are also known by their shorthand nomenclature, which represents the number of carbon atoms in their chain. The *n*-3 fatty acids are so called because their first carbon double bond is present at carbon number 3 counting the methyl carbon as carbon number 1 while *n*-6 are so called as their first carbon double bond is present at carbon number 6^(67,68).

Not all fatty acids can be synthesised *de novo* in mammals, as they cannot insert double bonds before carbon 9 in oleic acid (18 : 1*n*-9). Specifically, mammals cannot convert oleic acid into linoleic acid (LA; 18 : 2*n*-6) or LA into α -linolenic acid (ALA; 18 : 3*n*-3). Since ALA and LA cannot be synthesised *de novo*, their intake from food sources is important and they are classified as essential fatty acids (EFA). Although mammalian cells do not have the ability to synthesise LA and ALA, once these EFA are obtained from the diet they can be metabolised into physiologically active compounds via the introduction of extra double bonds and chain elongation through the processes of desaturation and elongation^(69,70) (Fig. 2). Furthermore, LA appears to be an EFA not only because of an immediate cellular function, but because it is the precursor of AA (20 : 4*n*-6) that has numerous essential functions. Similarly, the importance of dietary ALA is that it is the precursor of EPA and DHA which are found in the phospholipids of cell membranes (Fig. 2). EPA/DHA have a range of biological functions, with EPA demonstrating anti-inflammatory effects while DHA is recognised to be important for visual and neurological functions and vital for the growth and development of premature and newborn infants⁽⁶⁸⁾. Additionally, both EPA and DHA have been found to have roles in the resolution of inflammation⁽⁶⁸⁾. Subsequently, AA, EPA and DHA have been suggested to be termed as 'conditionally essential'^(71,72).

Fatty acids are important constituents of the phospholipids of all cell membranes and the characteristic fatty acid composition of different cells and tissues is dependent on the availability of different fatty acids as well as the metabolic properties of the cells and tissues^(68,73). Once PUFA are incorporated in cell membrane phospholipids they are proposed to be involved in the inflammatory cell response (Fig. 2)⁽⁷⁴⁾. Since tissue and blood fatty acid profiles have been shown to be modified by dietary intake, they have been used as compliance markers for dietary supplementation studies⁽⁷⁵⁻⁷⁷⁾. However, it has yet not




Fig. 2. Proposed pathway for the metabolism of *n*-6 and *n*-3 fatty acids, showing the production of *n*-3 and *n*-6 fatty acid-derived eicosanoids via the cyclo-oxygenase and 5-lipoxygenase enzymes. The *n*-9 fatty acids do not follow the same pathway, and subsequently are hypothesised to not play a role in inflammation. TX, thromboxane; LT, leukotriene.

explicitly been demonstrated that phospholipid or total lipid content of cells can be used as a marker of dietary intake whilst the differences between different cell populations are confounding variables in the literature. In adults, there are a number of epidemiological and supplementation studies evaluating the effects of dietary *n*-3 PUFA intake on asthma. In a population-based study (*n* 13 820; ages 42.2 (SD 11.2) years), individual fatty acid intakes (estimated by FFQ) were analysed and related to symptoms of asthma⁽⁷⁸⁾. The results demonstrate that a high intake of *n*-3 fatty acids did not protect against asthma; however, higher consumption of several *n*-6 fatty acids including LA and AA were found to be associated with a significant reduction in FEV₁, particularly in smokers⁽⁷⁸⁾. In another population-based study of Respiratory Health in Northern Europe, 16 187 subjects aged 23–54 years completed a postal FFQ and it was reported that a minimum level of weekly fish intake (>1 serving per week) in adulthood was associated with protection against asthma⁽⁷⁹⁾. Participants who never had fish were found to have an increased risk for asthma⁽⁷⁹⁾. It should be highlighted that the inconsistencies from the population-based studies are possibly due to the methods used. Most studies that have found associations between fatty acid intake and asthma have used indirect measurements of fatty acid intake including FFQ or other dietary recall methods⁽⁸⁰⁾.

The presence of *n*-3 fatty acids in the phospholipids of plasma, erythrocytes and even whole blood has been used as a marker for compliance in various supplementation studies. In addition, incorporation of fatty acids in inflammatory cells/membranes has been studied in inflammatory disease states^(80–83). Thus, it can be argued that studies using a direct marker of fat intake may provide a reliable method for evaluating the relationship between asthma and dietary *n*-3 PUFA. Some but not all studies show a possible agreement between dietary FFQ and plasma fatty acid levels; in a study by Woods *et al.*, it was demonstrated that *n*-3 PUFA and the *n*-6:*n*-3 ratio in plasma phospholipids were not consistently associated with asthma or atopy⁽⁸⁴⁾. The only positive association with current asthma was found with dihomo- γ -linolenic acid in plasma phospholipids. In this study, there was a good agreement between the dietary FFQ estimated fatty acid intake and the plasma fatty acid levels⁽⁸⁴⁾. The Global Allergy and Asthma European Network of Excellence (GA²LEN) has shown that a reasonable association exists between estimates of dietary *n*-3 PUFA and total plasma phospholipid composition using the GA²LEN FFQ within the European countries that took part in the study⁽⁷⁵⁾. In supplementation studies, while dietary estimates provide information about the dietary behaviour of individuals, the total cell or phospholipid content of fatty acids can be used as a reliable marker of incorporation.



***n*-3 Fatty acids and their lipid derivatives in the inflammatory process**

***n*-3 Fatty acid and arachidonic acid derivatives produced by cyclo-oxygenase and lipoxygenase pathways**

Eicosanoids are oxidised derivatives of twenty-carbon fatty acids and include prostaglandins, thromboxanes, LT and lipoxins (LX). The membrane phospholipids are the initial substrates for eicosanoid synthesis and due to the abundance of AA in phospholipids of inflammatory cells, AA is considered the major substrate for eicosanoid synthesis^(85–87). One of the mechanisms for the action of *n*-3 PUFA is the altered pattern of lipid mediator synthesis⁽⁸⁸⁾. The metabolites from EPA and AA form the basis for regulatory signals and the eicosanoid synthesis involves PUFA mobilisation from the cell membrane by various phospholipase enzymes, most notably phospholipase A₂. Following mobilisation; the free AA or EPA/DHA acts as a substrate for eicosanoid production via the COX and lipoxygenase (LOX) pathways. Prostaglandins, prostacyclins and thromboxanes are formed by the action of COX while LT and hydroxy fatty acids are formed by the action of LOX enzymes. The eicosanoids produced from the two families of fatty acids vary in biological activity. AA is one of the most tightly regulated fatty acids in cell membrane phospholipids as it affects the way cells behave, and its actions have far-ranging effects^(85,89). Diets high in LA or AA could potentially result in overactivity of AA-derived eicosanoids which could lead to an overactive immune system which has been hypothesised to cause damage to host tissues, lead to the formation of thrombi, and facilitate inflammatory disorders^(90–93). Despite the pro-inflammatory effects of AA-derived eicosanoids, it is now recognised that not all the metabolites from AA act in the same manner and some metabolites are shown to promote bronchodilation in normal subjects⁽⁹⁴⁾ but may cause constriction in patients with asthma because of activation of reflex cholinergic bronchoconstriction^(95,96).

EPA-derived eicosanoids produced via cyclo-oxygenase and lipoxygenase pathways

EPA is a competing substrate for COX and LOX enzymes and this competition with AA leads to decreased expression of COX-2 and 5-LOX^(74,92). This has been suggested as a potential mechanism for the proposed anti-inflammatory benefits of *n*-3 PUFA. Ordinarily, AA is metabolised by COX into biologically active 2-series prostanoids; however, when EPA is utilised as a COX substrate the resultant prostanoids are of the alternative 3-series which are known to be less pro-inflammatory^(93,97,98). In an *in vitro* study by Wada *et al.*⁽⁹⁹⁾ specificities of prostanoid enzymes and receptors towards EPA-derived and AA-derived prostaglandins were compared. There was a significant decrease in the formation of 2-series prostaglandins via PGHS-2 (prostaglandin endoperoxide H synthase-2) and this was demonstrated to occur only to the extent that AA levels in phospholipids were decreased by EPA replacing AA⁽⁹⁹⁾. Approximately two- to three-fold higher activities were observed for AA-derived mediators compared with EPA-derived ones with the different receptors studied. For example, lower potencies

were observed for PGE₃ compared with PGE₂ towards the EP1, EP2, EP3 and EP4 receptors⁽⁹⁹⁾. In a separate *in vitro* study it has been demonstrated that EPA-derived PGD₃ antagonises the effect of PGD₂-mediated migration of neutrophils across endothelial cells⁽¹⁰⁰⁾. These studies directly comparing the effect of EPA- and AA-derived lipid mediators provide some evidence to confirm the competition between *n*-6 and *n*-3 fatty acids for the production of eicosanoids and go some way towards identifying the possible mechanisms involved. It has also been shown that 5-series LT can be produced in the macrophages of *n*-3 fatty acid-fed mice⁽⁷⁰⁾ and in the neutrophils of human subjects supplemented with *n*-3 fatty acids for several weeks^(101–105). LTB₅ derived from EPA has been shown to be 10- to 100-fold less potent as a neutrophil chemotactic agent than AA-derived LTB₄; thus LTB₅ is a much weaker inducer of inflammation^(70,102). In an *n*-3 fatty acid supplementation study using EIB participants, it was found that there was a significant reduction in LTB₄ and significant increase in LTB₅ level in activated polymorphonuclear cells by the end of 3 weeks of supplementation and this reduced inflammatory effect was accompanied by an improvement in post-exercise EIB symptoms⁽⁵⁷⁾.

The modified cell membrane phospholipid fatty acid content with *n*-3 PUFA supplementation facilitates the formation of 'lipid rafts' which have been studied in T cells. These rafts are formed by the movement of receptors, accessory proteins, and enzymes within the plane of the cell membrane to co-localise into signalling platforms^(104,105). These rafts in turn influence the activity of membrane proteins including receptors, transporters, ion channels and cell signalling enzymes; these result in the transfer of intracellular signals into the cytosol⁽¹⁰⁶⁾. Based on the evidence from cell-culture and animal-feeding studies it has been shown that *n*-3 PUFA supplementation modifies raft formation in T cells, which in turn impairs the signalling mechanism of these cells^(107,108). Thus, the exposure of T cells to *n*-3 fatty acid supplementation can alter the chemical structure of rafts which can consequently affect their function^(109,110). Additionally, the supplementation of *n*-3 PUFA has been reported to affect cell signalling pathways either by altering the expression and activity of membrane receptors or by modifying the expression of genes by the activation of transcription factors such as NF-κB and PPAR-α^(111–113).

Evidence from *n*-3 intervention trials in asthma

The adult *n*-3 fatty acid intervention trials in the last two decades have provided a contradictory picture of efficacy with respect to FEV₁ or PEF. Table 2 summarises the main intervention trials with primary outcomes. Kirsch *et al.*⁽¹¹⁴⁾ compared a high-dose *n*-3 PUFA supplementation (4 g EPA/d; *n* 6) with a low dose (0.1 g/d; *n* 6) for 8 weeks on asthmatics in a small study (*n* 12; aged 42–73 years) and found there was no difference in FEV₁ or symptom scores between the two groups⁽¹¹⁴⁾. There was also no difference in the lung function determined by PEF between the two groups before the start of supplementation⁽¹¹⁴⁾. Hodge *et al.* reported no change in lung function values in asthmatic children (*n* 45; aged 8–12 years); however, there was a reduction in TNFα production (by cultured peripheral blood mononuclear cells) compared with

Table 2. Relevant trials of *n*-3 fatty acid supplementation in asthma

| Author | Study design | Intervention | Participants | Outcomes |
|---|---|---|---|---|
| Studies reporting benefits of <i>n</i>-3 supplementation | | | | |
| Arm <i>et al.</i> (1988) ⁽¹²¹⁾ | RCT, double-blind, placebo-controlled, parallel design Comparison of <i>n</i> -3 capsules with placebo supplementation 2-week run-in period followed by 10-week treatment period | <i>n</i> -3: 3.2 g EPA and 2.2 g DHA/d Placebo: Matched capsules with olive oil | 22 atopic, non-smoking asthmatic volunteers entered and 17 completed the trial Age 18–42 years Asthma severity determined from asthma symptoms and PEF measurements No participants were using oral steroids or theophylline or gave history of aspirin sensitivity | No changes for lung function outcomes, medication usage, dyspnoea 10-fold increase in neutrophil phospholipid EPA 50 % inhibition of total LTB (LTB ₄ and LTB ₅) generation by stimulated neutrophils Suppression of neutrophil chemotaxis |
| Stenius-Aarniala <i>et al.</i> (1989) ⁽⁸³⁾ | RCT cross-over design Three-arm comparison of fish oil <i>v.</i> evening primrose oil (<i>n</i> -6 group) <i>v.</i> olive oil using liquid oil supplementation 2-week run-in period followed by 30-week intervention (10 weeks per treatment arm) period No washout period | <i>n</i> -3: 3.6 g EPA and 2.2 g DHA Evening primrose oil: 72 % <i>cis</i> -linoleic acid, 9 % γ -linoleic acid Olive oil: Matched capsules with olive oil | 40 asthmatics selected, 36 entered study and 29 completed the study Age 19–61 years Asthma severity determined from asthma symptoms and PEF measurements | No differences in PEF, symptoms or medication usage Increases in plasma PGE ₂ levels, no changes in other TxB ₂ , PGF ₂ α and 6-keto-PGF ₁ - α in plasma or urine Significant increase in plasma fatty acid for EPA and DHA |
| Schubert <i>et al.</i> (2009) ⁽¹¹⁹⁾ | RCT, double-blind, parallel study 5-week supplementation; after 3 weeks, participants were challenged daily with low-dose house dust mite allergen (2 weeks) | <i>n</i> -3: 450 mg EPA and 180 mg DHA/d Placebo: Unsaturated fatty acids and MUFA | 23 house dust mite-allergic asthmatics (13 females and 10 males) Age 22–29 years Asthma severity determined from asthma symptom, skin prick, lung function and methacholine challenge | No improvement in PFT, AHR and number of serum neutrophils Reduction in FeNO <i>n</i> -3 fatty acid group compared with placebo after 3 weeks Significant reduction in eosinophilic cation protein and <i>in vitro</i> CystLT release Significant increase in erythrocyte and plasma membrane for EPA levels |
| Emelyanov <i>et al.</i> (2002) ⁽¹¹⁶⁾ | RCT, double-blind, parallel study, placebo-controlled 2-week run-in period, 8-week supplementation Two trials were reported: Trial 1: Randomised, prospective, double-blind, placebo-controlled, parallel-group trial Supplementation for 4 weeks Subjects were questioned about their asthma management using a non-validated questionnaire after 2 and 4 weeks Trial 2: Supplementation for 4 weeks | <i>n</i> -3: New Zealand green-lipped mussel extract (50 mg EPA and DHA/d) Placebo: 150 mg olive oil/d <i>n</i> -3: Low-dose medical food emulsion containing 0.75 g GLA + 0.5 g EPA, or 1.13 g GLA + 0.75 g EPA Placebo: Olive oil Low-dose medical food emulsion (same as trial 1), daily Quality of life and asthma management were measured using validated questionnaires | 46 mild–moderate atopic asthmatics Age 18–56 years Asthma diagnosis based on ATS guidelines (clinical history, reversibility of (FEV ₁ of 15 % and diurnal variability of PEF of >20 %, skin prick test to common inhalant allergens 35 atopic subjects with mild–moderate asthma 65 mild–moderate asthma subjects | Significant reduction in mean daytime wheeze in <i>n</i> -3 fatty acid group Improvement in mean morning PEF No change in mean FEV ₁ and evening PEF LT biosynthesis blocked with a dose of 1.13 g GLA + 0.75 g EPA Fasting plasma GLA and EPA levels plateaued within 7 d of daily consumption at all levels of intake Significant increase in plasma for EPA in 4 weeks Improved self-reported asthma status and medication use in participants consuming low- and high-dose emulsion between week 2 and week 4 Reduction in medication use with high dose Significantly improved quality-of-life and asthma management scores |
| Mickleborough <i>et al.</i> (2006) ⁽⁵⁷⁾ | RCT, double-blind, cross-over, placebo-controlled trial 3-week supplementation period in each arm 2-week washout phase | <i>n</i> -3: 3.2 g EPA and 2.0 g DHA Placebo: Matched capsules with olive oil | 16 subjects Age 23 \pm 1.6 years Participants with clinically treated mild–moderate asthma with a FEV ₁ >70 % predicted | Improved pulmonary function to below the diagnostic EIB threshold Reduction in medication usage Reduction in induced sputum differential cell count percentage and concentrations of LTC ₄ –LTE ₄ , PGD ₂ , IL-1 β and TNF- α before and following exercise on the <i>n</i> -3 fatty acid diet Significant reduction in LTB ₄ and a significant increase in LTB ₅ generation from activated polymorphonuclear cells on the <i>n</i> -3 fatty acid diet |

Table 2 *Continued*

| Author | Study design | Intervention | Participants | Outcomes |
|---|--|--|---|--|
| Mickleborough <i>et al.</i> (2003) ⁽¹²⁶⁾ | RCT, double-blind, cross-over study Subjects entered the study on their normal diet, and then received either fish oil capsules or placebo | <i>n</i> -3: 3.2 g EPA and 2.0 g of DHA Placebo: Matched capsules with olive oil | 10 athletes and 10 controls Age (asthmatics 23.2 ± 1.9 years; controls 22.4 ± 1.7 years) Participants with clinically diagnosed EIB | No effect on pre-exercise pulmonary function in either group Improved post-exercise pulmonary function Reduction in LTE ₄ , 9α, 11β-PG F ₂ , LTB ₄ , TNF-α, and IL-1β, on the <i>n</i> -3 PUFA diet compared with baseline and placebo diets and after exercise challenge |
| Studies reporting benefits of <i>n</i> -3 supplementation (in children) | | | | |
| Hodge <i>et al.</i> (1998) ⁽¹¹⁵⁾ | RCT, double-blind, parallel design Comparison of diet high in <i>n</i> -6 fatty acids and diet high in <i>n</i> -3 fatty acids 2-week run-in period followed by 6-month intervention period Dietary control: <i>n</i> -3 diet participants advised to eat fish at least once per month, <i>n</i> -6 group to avoid fish | <i>n</i> -3: 1.2 g <i>n</i> -3/d <i>n</i> -6: Safflowerseed/palm/olive oil | 45 asthmatic children Age 8–12 years Asthma defined as reported episodic wheeze in past 12 months and AHR, PFT, day and night symptoms and medication usage | No change in lung function values Reduction in TNF-α production (cell culture for peripheral blood mononuclear cells) compared with baseline Increase in plasma phospholipid <i>n</i> -3 fatty acid levels at 3 months compared with the <i>n</i> -6 group |
| Studies reporting no benefits of <i>n</i> -3 supplementation | | | | |
| McDonald <i>et al.</i> (1990) ⁽¹¹⁸⁾ | RCT, cross-over design, double-blind, placebo-controlled Comparison of <i>n</i> -3 fatty acid supplementation with placebo supplementation 10-week intervention period, 6-week washout and then 10-week cross-over intervention | <i>n</i> -3: 2.7 g EPA and 1.8 g DHA/d Placebo: 15 g olive oil/d Subjects asked to keep their dietary fish intake unchanged throughout the study | 15 non-smoking asthmatics Subjects aged 28 to 72 years completed the study 7 subjects were ex-smokers Asthma severity determined from asthma symptoms and PEF measurements | No change in PEF, medication usage or asthma symptoms after <i>n</i> -3 supplementation |
| Kirsch <i>et al.</i> (1988) ⁽¹¹⁴⁾ | RCT, double-blind, parallel design Compared high dose of EPA v. low dose of EPA supplementation 6-week run-in period, 8-week treatment period 2-week washout | High dose of EPA: 4 g EPA/d Low dose of EPA: 0.1 g EPA/d | 12 patients, aged 42–73 years Asthma severity determined from symptom index and physical evaluation | No change in clinical status (symptoms, hospital admissions) or pulmonary function throughout the study |
| Thien <i>et al.</i> (1993) ⁽¹²³⁾ | RCT, double-blind, placebo-controlled, parallel design Comparison of <i>n</i> -3 supplementation with placebo supplementation 6-month supplementation | <i>n</i> -3: 3.2 g EPA + 2.2 g DHA/d Placebo: Olive oil (volume not specified) | 37, non-smoking, pollen-sensitive adults Age 19–42 years Asthma severity determined by symptom, medication usage, PEF measurements and AHR | No changes in PFT, medication usage or other parameters including symptoms, airway conductance and AHR |

RCT, randomized controlled trial; PEF, peak expiratory flow; LT, leukotriene; Tx, thromboxane; PFT, pulmonary function test; AHR, airway hyper-responsiveness; FeNO, fractional exhaled NO; CystLT, cysteinyl LT; ATS, American Thoracic Society; FEV₁, forced expiratory volume in 1 s; GLA, γ-linolenic acid; EIB, exercise-induced bronchoconstriction.

baseline; however, the magnitude of change between groups was not significant⁽¹¹⁵⁾. PEF has been reported in some studies as a marker for lung function. Emelynov *et al.* showed a significant increase in morning PEF with 8 weeks of supplementation with a low dose of n-3 fatty acids (50 mg EPA + DHA per d) in mild-moderate atopic asthmatics (*n* 46; aged 18–56 years)⁽¹¹⁶⁾. In addition, Surette *et al.* reported a significant improvement in quality of life and asthma management scores (including symptoms) assessed by questionnaires after 3 weeks of supplementation (0.5 g EPA + 0.75 g DHA per d; *n* 65, mild-moderate asthmatics)⁽¹¹⁷⁾. Conversely, in two cross-over trials there was no significant change in PEF after 10 weeks of n-3 fatty acid supplementation with >2 g EPA + DHA per d^(83,118). Overall, some studies and our knowledge of the physiological action of n-3 fatty acids suggest that we should potentially see effects of supplementation on lung function; the lack of consistent effect of n-3 fatty acid supplementation on FEV₁ or PEF could be attributed to the heterogeneity between the studies. These studies have used a range of doses, as low as 50 mg to >3 g of EPA/DHA per d and have studied different subgroups of asthmatics such as mild-moderate, severe and atopic populations.

In a study by Schubert *et al.* (*n* 23; atopic asthma) dietary supplementation with either an n-3 PUFA-enriched fat blend (0.69 g/d, comprising 450 mg EPA and 180 mg DHA per d; twelve participants) or placebo (thirteen participants) for 5 weeks was provided⁽¹¹⁹⁾. After 3 weeks of supplementation, the participants underwent two allergen challenge tests in the remaining 2 weeks of supplementation. FeNO was significantly lower in the n-3 PUFA group ($P=0.01$); though the levels of FeNO increased during allergen exposure in both groups, the mean values were 5-fold lower in the n-3 PUFA group. No differences were observed between the asthmatic and control groups with regards to asthma symptoms, FEV₁ or the allergen dose required to induce deterioration of lung function challenge. Furthermore, compliance was monitored by plasma and erythrocyte cell membrane fatty acid composition and it was found that 2 weeks of supplementation led to a 3-fold higher value of EPA in the n-3 PUFA group compared with placebo and these levels were maintained till the end of supplementation in plasma and erythrocyte cell membranes⁽¹¹⁹⁾.

In a double-blind, placebo-controlled pilot study, a 2-week supplementation with n-3 fatty acids (dose: 0.9 g EPA and 0.65 g DHA/d; *n* 20) showed no changes in FeNO levels, FEV₁ or asthma quality-of-life questionnaires⁽¹²⁰⁾. However, this study was not well controlled as the participants were on their regular medication of inhaled corticosteroids, which confounds the effect of n-3 PUFA supplementation on pulmonary function and other outcomes. Furthermore, the low dose and duration of supplementation may be a reason why no effect of n-3 fatty acid supplementation was observed. In addition, the participants in this study had stable asthma following their corticosteroid usage and their FeNO levels were not significantly elevated (28 parts per billion) compared with healthy individuals (25 parts per billion)⁽¹²⁰⁾. Due to these reasons, the exact relationship of n-3 PUFA supplementation and FeNO was difficult to evaluate.

Asthmatics have a reliance on pharmacological medication and despite the significant advancement in asthma medication

during the last two decades the treatments are still far from ideal^(2,61). Some of the earlier intervention trials have not shown any significant changes to reliance on medication^(118,121). Hodge *et al.*⁽¹¹⁵⁾ have shown a significant reduction in medication use in asthmatic children after 9-month supplementation with 1.2 g EPA + DHA per d⁽¹¹⁵⁾, while Mickleborough *et al.* have reported that bronchodilator use was significantly reduced during the last 2 weeks of n-3 fatty acid supplementation (3.2 g EPA + 2.2 g DHA per d) in EIB-prone adults⁽⁵⁷⁾. Furthermore, it has been reported that there are improvements in self-reported asthma status and bronchodilator use in subjects consuming an n-3 emulsion (1 g EPA + 1.5 g γ -linolenic acid per d) for 4 weeks compared with a placebo⁽¹¹⁷⁾. The authors have also reported results from another trial showing an improvement in the asthma quality of life and asthma control based on non-validated questionnaires (primarily based on bronchodilator usage)⁽¹¹⁷⁾.

Chronic inflammation is associated with AHR, which is responsible for recurrent episodes of wheezing, breathlessness, chest tightness and coughing among asthmatics. The majority of intervention studies in children show inconsistencies when reporting effects of n-3 fatty acids on AHR⁽¹²²⁾. There is a need for further studies in children to understand the effect of n-3 fatty acid supplementation in asthma. Studies^(121,123) have reported AHR in terms of the provocation dose of histamine required to produce a 35 % fall in specific conductance and showed no effect of n-3 fatty acid supplementation on AHR. In children, Nagakura *et al.*⁽¹²⁴⁾ reported AHR as the provocative concentration of acetylcholine causing a 20 % fall in FEV₁ for each subject and saw a reduction in acetylcholine responsiveness in the n-3 fatty acid group but not in the control group⁽¹²⁴⁾. Schubert *et al.*⁽¹¹⁹⁾ reported a reduction in AHR after an allergen challenge with n-3 fatty acid supplementation; however, this change failed to reach significance⁽¹¹⁹⁾.

Overall the evidence from *in vitro* and *in vivo* studies shows that n-3 PUFA supplementation has the potential for inhibiting T cell proliferation and production of cytokines. Inhibition of T cell responses has been observed with higher dosage of n-3 fatty acids while this effect is not observed at low n-3 fatty acid levels. These inconsistencies may be related to differences in subject characteristics including age, sex, health, diet, differences in study design (dose and duration) as well as experimental methods (cell preparation, cell culture, cytokine assays). In conclusion, there is evidence to suggest that n-3 fatty acids may modulate T cell response and functions independently of eicosanoid production^(125,126). Furthermore, increasing phospholipid EPA:AA ratios in inflammatory cells with dietary n-3 fatty acid supplementation is likely to be one of the mechanisms that can potentially facilitate the production of weaker eicosanoids that may exhibit anti-inflammatory effects. Thus, there are different mechanisms for the immunomodulatory action of n-3 PUFA, which require further verification in *in vivo* human studies.

New class of lipid mediators in resolution of inflammation

In the last decade, several lipid mediators have been identified that have a potential role in the resolution of inflammation. Towards the end of an inflammatory process, there is

neutralisation and elimination of pathogens, followed by removal of cellular components to prevent excessive tissue damage^(92,127). The mechanism of resolution is continuous with a decrease in the number of inflammatory cells, there is a reduction in the levels of pro-inflammatory cytokines and eicosanoids 'switch' from being inflammatory in nature (LT, PG, etc.) to anti-inflammatory or specialised pro-resolving mediators such as LX, resolvins (Rv), protectins (PD) and maresins⁽¹²⁸⁾ (Fig. 3). These mediators have the potential to control the duration and magnitude of inflammation^(128,129). These Rv, PD and maresin mediators are produced from *n*-3 PUFA (EPA and DHA). The accessibility, affordability and lack of health side effects related to *n*-3 fatty acid supplementation have generated interest in these potent mediators for research studies in human subjects with or without inflammatory diseases⁽¹³⁰⁾. Serhan *et al.*^(131–133) identified, characterised and explained families of pro-resolving lipid metabolites from EPA and DHA using a lipidomics approach^(131–133). There are two classes of Rv, the E-series derived from EPA and D-series derived from DHA (Fig. 3). It has been suggested that once the inflammatory process reaches initial resolution phases, there is a 'switch' from the inflammatory nature of AA-derived metabolites (LT, PG, etc.) to anti-inflammatory or specialised pro-resolving LX which stop leucocyte recruitment and help promote generation of lipid mediators such as Rv and PD^(134,135).

Resolution of inflammation in airway diseases involves the removal of inflammatory cells from injured tissues, which is driven by apoptosis of leucocytes and elimination from the tissues^(136,137). The LX demonstrate their anti-inflammatory effects by reducing the formation of reactive oxygen species by leucocytes, decreasing transendothelial migration of leucocytes, and promoting non-phlogistic phagocytosis⁽¹³⁸⁾. LX also stop neutrophil infiltration and hence stop local inflammatory signals^(132,139,140). In asthmatics, there is decreased generation of LX and this is particularly explained by the deregulated expression of LX biosynthetic genes which vary by disease severity and anatomic compartment⁽¹⁴¹⁾. The only study assessing the relationship between LX and EIB has been conducted in children (aged 6–17 years; *n* 12) and it was reported that children with EIB have lower levels of circulating LXA₄ than healthy controls⁽¹⁴²⁾. Overall, it has been suggested that LX are generated in airways during airway inflammation and any reduction in the generation of LX could lead to persistent inflammation and contribute to the pathogenesis of asthma^(142,143).

The DHA-derived D-series Rv are involved in resolution by preventing TNF- α from making pro-inflammatory cytokines which would be responsible for cascading neutrophil infiltration^(131,144). A group of D-series Rv are aspirin triggered after acetylation of the COX-2 enzyme by aspirin and its interaction with DHA. It has been hypothesised that Rv and PD are a part of molecular mechanisms that highlight the role of aspirin in enhancing the conversion of EPA and DHA to Rv of the E- and D-series^(133,145). The E-series Rv are found in two major forms – RvE1 and RvE2. RvE1 has been found to exhibit its activity by responding to neutrophils. RvE1 impedes the migration of polymorphonuclear cells (PMN) to the site of inflammation, stops the PMN response to inflammatory cytokines and

promotes the clearance of inflammatory cells via phagocytosis by macrophages⁽¹³⁵⁾. Furthermore, RvE1 has been found to block the synthesis of pro-inflammatory cytokines and induce apoptosis and phagocytosis by up-regulation of chemokine receptor type 5⁽¹⁴⁶⁾. RvE1 has been shown to be involved in the suppression of the production of cytokines such as IL-1, IL-2, IL-6 and TNF- α ^(147,148), as well as facilitating wound healing⁽¹⁴⁹⁾. Recent animal models have shown that RvE1 regulates IL-23 and LXA₄ to promote resolution of allergic airway inflammation in a mouse model of asthma^(150–152). RvE1 can act along with LX as resolution-phase mediators to regulate IL-17 while only RV have the ability to regulate IL-23 and IFN- γ levels⁽¹⁵¹⁾. In other animal models, it has been shown that RvE1 is highly potent when supplied intraperitoneally before and during sensitisation and aeroallergen challenge phases⁽¹⁵³⁾. This concept has been further investigated to confirm that administration with RvE1 in allergic asthma (murine models) can prevent the development of AHR, mucous metaplasia, eosinophil accumulation, and Th2 cytokine generation, for example, IL-13⁽¹⁴⁵⁾. Haworth *et al.* have reported in murine models that NK cells express CMKLR1 (chemokine-like receptor 1; a receptor for RvE1), and depletion of NK cells leads to a reduction in RvE1-mediated resolution of allergic inflammation⁽¹⁵⁰⁾. Subsequently these findings signify novel functions of NK cells in facilitating resolution of adaptive immune responses and emphasise that NK cells are possible targets for specialised resolution-phase lipid mediators for clearance of activated T cells from injured or inflamed lungs⁽¹⁵⁰⁾. While the functions of RvE1 have been investigated thoroughly, there is less information available about the specific activity of RvE2. This mediator has been reported to be produced by neutrophils and acts in a similar manner as RvE1^(130,131). The two forms of E-series Rv have been hypothesised to have separate receptors as there is an additive effect when the two types of Rv are administered together⁽¹⁴³⁾.

PD, maresins and D-series Rv are DHA-derived lipid mediators and they function as anti-inflammatory molecules by blocking the activation and migration of neutrophils to sites of inflammation and reduce the production of pro-inflammatory cytokines^(129–133,154). In healthy individuals, airways and other mucosal surfaces have been found to be enriched with DHA while those individuals with asthma/cystic fibrosis have low levels of DHA⁽¹⁵⁵⁾. There is little evidence related to the effects of D-series Rv, maresins, and other DHA-derived mediators in asthma and only PD1 has been investigated. To date no receptors for PD have been found, although like RvE2 there is a combined effect with RvE1, suggesting distinct receptors for the two mediators^(135,155). PD1 has been reported to facilitate the expression of CCR5 ligands on neutrophils and to inhibit NF- κ B induction, which prevents the migration of neutrophils⁽¹⁵⁶⁾.

The biological characteristics of these new anti-inflammatory and pro-resolving mediators and the pathways that drive the formation and actions of these molecules have provided a new concept for treating inflammatory diseases. The majority of studies conducted have been in animal models including mice, rats and rabbits, with limited studies on human subjects. Most recently, in a clinical trial designed by Resolvix, the phase 2 results show that when RX-10045 (a Rv) is administered as a tropic eye drop for the treatment of patients with chronic dry




Fig. 3. Lipid mediators derived from arachidonic acid (AA), EPA and DHA. COX, cylo-oxygenase; LOX, lipoxygenase; RvE1, resolvins E1; RvE2, resolvins E2.

eye syndrome there was a dose-dependent improvement in both the signs and symptoms of dry eye, and the intervention did not show any health side effects⁽¹⁵⁷⁾. This first clinical study of the effect of Rv in human subjects will help improve the understanding of the agents that can stimulate the resolution mechanisms and resolve acute inflammation along with chronic inflammation to reduce human diseases where uncontrolled inflammation forms the basis of their pathophysiology⁽¹³¹⁾. Early-phase trials are currently on going using natural and synthetic Rv in various disease conditions such as asthma, inflammatory bowel disease, and other related inflammatory diseases; however, no information about the appropriate dosage of these compounds has been publicised. Based on a renal reperfusion study with 23–28 g mice, intravenous Rv dosage ranged from 0.01 to 0.1 mg/kg⁽¹⁵⁸⁾, while in another study investigating the effect of RvE1 in the asthma mouse model, a reduction in airway mucous, AHR and leucocyte bronchoalveolar lavage was achieved with intravenous dosages of 50–200 ng/mouse⁽¹⁵¹⁾. Furthermore, Xu *et al.* have recently shown that a dose of only 10 ng/mouse of RvE1 and RvD1 is sufficient to reduce inflammation and pain via regulation of the central and peripheral nervous system⁽¹⁵⁹⁾.

A recent study investigated the protective effect of a different form of marine oil (PCSO-524TM; lyprinol[®]/omega XL[®]), a stabilised lipid extract from New Zealand green-lipped mussel, *Perna canaliculus*, in treating airway inflammation and hyperpnoea-induced bronchoconstriction in asthmatic patients⁽¹⁶⁰⁾. A moderate dose of this lipid extract (containing 400 mg n-3 PUFA; 72 mg EPA and 48 mg DHA) over 3 weeks was shown to significantly reduce airway inflammation and bronchoconstriction after a dry gas airway challenge. Additionally there was reduced bronchodilator usage and

improved symptom scores. The levels of EPA/DHA in this recent study are comparable with the dose studied by Emelyanov *et al.*⁽¹¹⁶⁾, using PCSO-524TM; however, the mechanisms underlying the reduction in airway inflammation and improvement in lung function are not well established. The strong anti-inflammatory effect of PCSO-524TM has been suggested to be due to the nature of this extract comprising of up to ninety-one fatty acid components, including furan acid that is being argued to exhibit more potent anti-inflammatory activity than EPA⁽⁶¹⁾.

To summarise, LX, Rv, PD and maresins have been identified to have potent action (in the nanomolar and picomolar range) in a variety of cell types *in vitro*, as well as in many *in vivo* models of inflammatory diseases. Human supplementation studies are required to evaluate the action of these novel lipid mediators in other diseases including asthma. Furthermore, dose–response studies are required to elucidate the most appropriate dose for the anti-inflammatory effects. Since Rv, PD and maresins are biological molecules derived from n-3 PUFA which are integral components of cell membrane phospholipids, these molecules are suggested to regulate pleiotropic effects via cell signalling. Furthermore, these characteristics distinguish the lipid mediators from industrially produced drugs and what have been conventionally regarded as primary biological therapeutic agents, which have been shown to exhibit more limited and specific effects⁽¹³²⁾. However, the major challenges that have limited the application of these new mediators are the standardisation of appropriate methods for measurement of these in a laboratory setting. Other areas of interest in recent years have been a comparison of the health benefits of EPA and DHA supplementation *v.* treatment with Rv or PD. The differences, similarity and acceptance of health

benefits of dietary *n*-3 PUFA and/or their mediators will be dependent on factors such as costs, safety and public health implications that are affected as a result of adopting a particular treatment approach⁽¹³⁰⁾. Thus, well-designed trials are required to understand the efficacy of these novel mediators in inflammation.

Summary

Though the currently available pharmacological therapies for asthma and EIB are effective, long-term usage of these therapies is associated with issues of tachyphylaxis and health side effects. Complementary therapies are becoming gradually more popular among individuals with asthma for management of their symptoms. Increasing evidence from observational and intervention studies has suggested the possible anti-inflammatory effects of *n*-3 fatty acids on various chronic inflammatory diseases, including asthma and there is, therefore, an impetus towards using *n*-3 fatty acids as a complementary therapy. There are no major health side effects associated with the dietary supplementation of *n*-3 fatty acids, thereby making *n*-3 supplementation an attractive non-pharmacological intervention which may assist with the management of symptoms. The anti-inflammatory effect of *n*-3 fatty acids has been linked to a change in cell membrane composition, with *n*-3 fatty acid supplementation (primarily EPA and DHA) modifying lipid mediator generation by producing a less inflammatory series of eicosanoids. A newly identified group of lipid mediators produced from the oxidation of *n*-3 fatty acids (EPA and DHA) include Rv and PD, which have also been suggested as key players in the resolution of inflammation. Reduced inflammation attenuates the severity of asthma including symptoms (dyspnoea) and thereby exerts a bronchodilatory effect.

The *n*-3 fatty acid intervention studies on asthmatics have shown that there is a possible beneficial role of *n*-3 on asthma as well as EIB. There is a consensus within the literature that *n*-3 PUFA exert a range of anti-inflammatory effects and that they do not demonstrate any major negative side effects. The advantages of using *n*-3 PUFA supplementation in asthma have been widely reviewed and their effectiveness as a complementary therapy is acknowledged. However, there are some studies which show that there may be subgroups of asthmatics (EIB and allergic asthma) who benefit greatly and others who do not benefit from long-chain *n*-3 PUFA. Inconsistencies in study outcomes may be as a direct result of different dosages and durations of supplementation whilst the impact of investigating different subclassifications of asthma (each having its own characteristic inflammatory pattern) cannot be underestimated. Further studies differentiating asthma subgroups with specific phenotype/genotype profiles are required where specific physiological and biochemical characteristics of these groups are monitored with *n*-3 fatty acid supplementation. In addition, a number of studies on inflammation have suggested a threshold for an anti-inflammatory effect exhibited by *n*-3 fatty acids to be exerted in the range of 1.3–2.7 g EPA per d in both adults and children. Thus, appropriate dose should be considered when designing the studies. Finally, there is paucity of data relating to *n*-3 fatty acid supplementation and EIB with

studies that have been conducted focusing primarily on athletes. There is a need for structured studies in both adults and children to respond to identified gaps in the current literature to move forward the field of asthma research.

Acknowledgements

There are no individuals who contributed to the present review other than the authors as listed. The authors thank Loughborough University for providing research facilities and research funds.

All authors fulfilled conditions of authorship: (1) substantial contributions to conception and design of the manuscript; (2) drafting the manuscript or revising it critically for intellectual content; and (3) final approval for the version to be published.

There were no external funds associated with the present review.

The authors declare no conflicts of interest.

References

1. Bousquet J, Bousquet PJ, Godard PJ, *et al.* (2005) The public health implications of asthma. *Bull World Health Organ* **83**, 548–554.
2. Global Initiative for Asthma (GINA) (2011) From the global strategy for asthma management and prevention. <http://www.ginasthma.org/> (accessed August 2012).
3. Koshy G, Delpishah A & Brabin BJ (2010) Trends in prevalence of childhood and parental asthma in Merseyside, 1991–2006. *J Public Health (Oxf)* **32**, 488–495.
4. Ronchetti R, Villa MP, Barreto M, *et al.* (2001) Is the increase in childhood asthma coming to an end? Findings from three surveys of schoolchildren in Rome, Italy. *Eur Respir J* **17**, 881–886.
5. McFadden ER Jr & Gilbert IA (1994) Exercise-induced asthma. *N Engl J Med* **330**, 1362–1367.
6. Anderson SD & Holzer K (2000) Exercise-induced asthma: is it the right diagnosis in elite athletes? *J Allergy Clin Immunol* **106**, 419–428.
7. Rundell KW, Spiering BA, Judelson DA, *et al.* (2003) Bronchoconstriction during cross-country skiing: is there really a refractory period? *Med Sci Sports Exerc* **3**, 18–26.
8. Suman OE, Beck KC, Babcock MA, *et al.* (1999) Airway obstruction during exercise and isocapnic hyperventilation in asthmatic subjects. *J Appl Physiol* **87**, 1107–1113.
9. Anderson SD & Kippelen P (2012) Assessment and prevention of exercise-induced bronchoconstriction. *Br J Sports Med* **46**, 391–396.
10. Hallstrand TS (2012) New insights into pathogenesis of exercise-induced bronchoconstriction. *Curr Opin Allergy Clin Immunol* **12**, 42–48.
11. Barnes PJ (2001) Th2 cytokines and asthma: an introduction. *Respir Res* **2**, 64–65.
12. Brightling CE, Gupta S, Gonen S, *et al.* (2012) Lung damage and airway remodelling in severe asthma. *Clin Exp Allergy* **42**, 638–649.
13. Kraft M (1999) The distal airways: are they important in asthma? *Eur Respir J* **1**, 1403–1417.
14. Hallstrand TS, Moody MW, Wurfel MM, *et al.* (2005) Inflammatory basis of exercise induced bronchoconstriction. *Am J Respir Crit Care Med* **172**, 679–686.
15. Shifren A, Witt C, Christie C, *et al.* (2012) Mechanisms of remodeling in asthmatic airways. *J Allergy (Cairo)* **2012**, 316049.

16. Rasmussen SB, Reinert LS & Paludan SR (2009) Innate recognition of intracellular pathogens: detection and activation of the first line of defense. *APMIS* **117**, 323–337.
17. Widgerow AD (2012) Cellular resolution of inflammation – catabasis. *Wound Repair Regen* **20**, 2–7.
18. Barnes PJ (2008) The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest* **118**, 3546–3556.
19. Robinson DS (2010) The role of the T cell in asthma. *J Allergy Clin Immunol* **126**, 1081–1093.
20. Canöz M, Erdenen F, Uzun H, *et al.* (2008) The relationship of inflammatory cytokines with asthma and obesity. *Clin Invest Med* **31**, E373–E379.
21. Broughton KS, Johnson CS, Pace BK, *et al.* (1997) Reduced asthma symptoms with *n*-3 fatty acid ingestion are related to 5-series leukotriene production. *Am J Clin Nutr* **65**, 1011–1017.
22. De Caterina R & Basta G (2001) *n*-3 Fatty acids and the inflammatory response – biological background. *Eur Heart J Suppl* **3**, D42–D49.
23. Barnes PJ (2011) Pathophysiology of allergic inflammation. *Immunol Rev* **242**, 31–50.
24. Bloemen K, Verstraelen S, van den Heuvel R, *et al.* (2007) The allergic cascade: review of the most important molecules in the asthmatic lung. *Immunol Lett* **113**, 6–18.
25. Swedin L, Neimert-Andersson T, Hjoberg J, *et al.* (2009) Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. *Eur Respir J* **34**, 200–208.
26. Deykin A & Kharitonov SA (2002) Nitric oxide. In *Asthma and COPD: Basic Mechanisms and Clinical Management*, pp. 307–314 [PJ Barnes, JM Drazen, SI Rennard and NC Thomson, editors]. London: Academic Press.
27. Palmer RM, Ferrige AG & Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature* **327**, 524–526.
28. Puckett JL & George SC (2008) Partitioned exhaled nitric oxide to non-invasively assess asthma. *Respir Physiol Neurobiol* **163**, 166–177.
29. Ricciardolo FL (2003) eNOS–iNOS paradigm and arginase in asthma. *Trends Pharmacol Sci* **24**, 560–561.
30. Lehtimäki L, Kankaanranta H, Saarelainen S, *et al.* (2001) Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. *Am J Respir Crit Care Med* **163**, 1557–1561.
31. Kharitonov SA, Chung KF, Evans D, *et al.* (1996) Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. *Am J Respir Crit Care Med* **153**, 1773–1780.
32. Saleh D, Ernst P, Lira S, *et al.* (1998) Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. *FASEB J* **12**, 929–937.
33. Zitt M (2005) Clinical applications of exhaled nitric oxide for the diagnosis and management of asthma: a consensus report. *Clin Ther* **27**, 1238–1250.
34. Jatakanon A, Lim S, Kharitonov SA, *et al.* (1998) Correlation between exhaled nitric oxide, sputum eosinophils and methacholine responsiveness. *Thorax* **53**, 91–95.
35. Lim S, Jatakanon A, Meah S, *et al.* (2000) Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. *Thorax* **55**, 184–188.
36. Sandrini A, Taylor DR, Thomas PS, *et al.* (2010) Fractional exhaled nitric oxide in asthma: an update. *Respirology* **15**, 57–70.
37. Miller MR, Hankinson J, Brusasco V, *et al.* (2005) Standardisation of spirometry. *Eur Respir J* **26**, 319–338.
38. Miller MR, Crapo R, Hankinson J, *et al.* (2005) General considerations for lung function testing. *Eur Respir J* **26**, 153–161.
39. Levy BD, De Sanctis GT, Devchand PR, *et al.* (2002) Multipronged inhibition of air way hyper-responsiveness and inflammation by lipoxin A₄. *Nat Med* **10**, 18–23.
40. Chung KF & Adcock I (2000) Asthma: application of cell and molecular biology techniques to unravel causes and pathophysiological mechanisms. In *Asthma: Mechanisms and Protocols*, pp. 1–29 [KF Chung and I Adcock, editors]. Totowa, NJ: Humana Press.
41. Reddel HK, Taylor DR, Bateman ED, *et al.* on behalf of the American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations (2009) An Official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* **180**, 59–99.
42. Agache I, Akdis C, Jutel M, *et al.* (2012) Untangling asthma phenotypes and endotypes. *Allergy* **67**, 835–846.
43. Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* **18**, 716–725.
44. Kerstjens HA, Brand PL, de Jong PM, *et al.* (1994) Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. *Thorax* **49**, 1109–1115.
45. American Thoracic Society & American College of Chest Physicians (2003) Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* **167**, 211–277.
46. Parsons JP, Kaeding C, Phillips G, *et al.* (2007) Prevalence of exercise-induced bronchospasm in a cohort of varsity college athletes. *Med Sci Sports Exerc* **39**, 1487–1492.
47. Rundell KW, Im J, Mayers LB, *et al.* (2001) Self-reported symptoms and exercise-induced asthma in the elite athlete. *Med Sci Sports Exerc* **33**, 208–213.
48. Rundell KW & Sue-Chu M (2010) Field and laboratory exercise challenges for identifying exercise-induced bronchoconstriction. *Breathe* **7**, 34–42.
49. Department of Health (2011) UK physical activity guidelines. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213744/dh_128257.pdf (accessed October 2014).
50. Crapo RO, Casaburi R, Coates AL, *et al.* (2000) Guidelines for methacholine and exercise challenge testing – 1999. *Am J Respir Crit Care Med* **161**, 309–329.
51. Barnes PJ (2010) New therapies for asthma: is there any progress? *Trends Pharmacol Sci* **31**, 335–343.
52. National Asthma Education and Prevention Program & Third Expert Panel on the Diagnosis and Management of Asthma (2007) Section 2, definition, pathophysiology and pathogenesis of asthma, and natural history of asthma. <http://www.ncbi.nlm.nih.gov/books/NBK7223/> (accessed October 2014).
53. Holgate ST (2008) Pathogenesis of asthma. *Clin Exp Allergy* **38**, 872–897.
54. Carlsen KH, Anderson SD, Bjermer L, *et al.* (2008) Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA²LEN. *Allergy* **63**, 492–505.
55. Priftis KN, Papadimitriou A, Gatsopoulou E, *et al.* (2006) The effect of inhaled budesonide on adrenal and growth suppression in asthmatic children. *Eur Respir J* **27**, 316–320.



56. Millward DT, Tanner LG & Brown MA (2010) Treatment options for the management of exercise-induced asthma and bronchoconstriction. *Phys Sportsmed* **38**, 74–80.
57. Mickleborough TD, Lindley MR, Ionescu AA, *et al.* (2006) Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. *Chest* **129**, 39–49.
58. Spector S & Tan R (2012) Exercise-induced bronchoconstriction update: therapeutic management. *Allergy Asthma Proc* **33**, 7–12.
59. Asthma UK (2014) Complementary therapies. <http://www.asthma.org.uk/about-asthma/medicines-treatments/complementary-therapies/> (accessed October 2014).
60. NHS (2014) Asthma – treatment. <http://www.nhs.uk/Conditions/Asthma/Pages/Treatment.aspx> (accessed October 2014).
61. Mickleborough TD & Lindley MR (2013) Omega-3 fatty acids: a potential future treatment for asthma? *Rev Respir Med* **7**, 577–580.
62. Rustan AC & Drevon CA (2005) *Fatty acids: structures and properties*. In *eLS*, 000389. Chichester: John Wiley & Sons Ltd; <http://www.els.net>
63. Bagby SP (2004) Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? *J Am Soc Nephrol* **15**, 2775–2791.
64. López S, Bermúdez B, Abia R, *et al.* (2010) The influence of major dietary fatty acids on insulin secretion and action. *Curr Opin Lipidol* **21**, 15–20.
65. Kennedy A, Martinez K, Chuang CC, *et al.* (2009) Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. *J Nutr* **139**, 1–4.
66. Woodside JV, McKinley MC & Young IS (2008) Saturated and *trans* fatty acids and coronary heart disease. *Curr Atheroscler Rep* **10**, 460–466.
67. Lunn J & Theobald H (2006) The health effects of dietary unsaturated fatty acids. *Nutr Bull* **31**, 178–224.
68. Calder PC & Yaqoob P (2009) Understanding omega-3 polyunsaturated fatty acids. *Postgrad Med* **121**, 148–157.
69. Ratnayake WM & Galli C (2009) Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. *Ann Nutr Metab* **55**, 8–43.
70. Wall R, Ross RP, Fitzgerald GF, *et al.* (2010) Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. *Nutr Rev* **68**, 280–289.
71. Burke PA, Ling PR, Forse RA, *et al.* (1999) Conditionally essential fatty acid deficiencies in end-stage liver disease. *Nutrition* **15**, 302–304.
72. Kidd PM (2007) Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. *Altern Med Rev* **12**, 207–227.
73. Calder PC (2010) Omega-3 fatty acids from fish and plants: same family, different biological activity. *Nutr Ther Metab* **28**, 101–109.
74. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. *Biochim Biophys Acta* **1851**, 469–484.
75. Garcia-Larsen V, Luczynska M, Kowalski ML, *et al.* (2011) Use of a common food frequency questionnaire (FFQ) to assess dietary patterns and their relation to allergy and asthma in Europe: pilot study of the GA²LEN FFQ. *Eur J Clin Nutr* **65**, 750–756.
76. Hodson L, Skeaff M & Fielding BA (2008) Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res* **47**, 348–380.
77. Jeppesen C, Jørgensen ME & Bjerregaard P (2012) Assessment of consumption of marine food in Greenland by a food frequency questionnaire and biomarkers. *Int J Circumpolar Health* **71**, 18361.
78. McKeever TM, Lewis SA, Cassano PA, *et al.* (2008) The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults. *Thorax* **63**, 208–214.
79. Laerum BN, Wentzel-Larsen T, Gulsvik A, *et al.* (2007) Relationship of fish and cod oil intake with adult asthma. *Clin Exp Allergy* **37**, 1616–1623.
80. Woods RK, Walters EH, Raven JM, *et al.* (2003) Food and nutrient intakes and asthma risk in young adults. *Am J Clin Nutr* **78**, 414–421.
81. Harris WS (2010) The omega-3 index: clinical utility for therapeutic intervention. *Curr Cardiol Rep* **12**, 503–508.
82. Kumar A, Lindley MR & Mastana SS (2014) A time efficient adaptation of GC-FID method for the analysis of PBMC lipid composition. *J Biochem Tech* **5**, 760–764.
83. Stenius-Aarniala B, Aro A, Hakulinen A, *et al.* (1989) Evening primrose oil and fish oil are ineffective as supplementary treatment of bronchial asthma. *Ann Allergy* **62**, 534–537.
84. Woods RK, Raven JM, Walters EH, *et al.* (2004) Fatty acid levels and risk of asthma in young adults. *Thorax* **59**, 105–110.
85. Calder PC (2012) Mechanisms of action of (omega-3) fatty acids. *J Nutr* **142**, 592S–599S.
86. Endres S, Ghorbani R, Kelley VE, *et al.* (1989) The effect of dietary supplementation with omega-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med* **320**, 265–271.
87. Rees D, Miles EA, Banerjee T, *et al.* (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. *Am J Clin Nutr* **83**, 331–342.
88. Tvrzicka E, Kremmyda LS, Stankova B, *et al.* (2011) Fatty acids as biocompounds: their role in human metabolism, health and disease – a review. Part 1: classification, dietary sources and biological functions. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* **155**, 117–130.
89. Seeds MC & Bass DA (1999) Regulation and metabolism of arachidonic acid. *Clin Rev Allergy Immunol* **17**, 5–26.
90. Levick SP, Loch DC, Taylor SM, *et al.* (2007) Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. *J Immunol* **178**, 641–646.
91. Miller SB (2006) Prostaglandins in health and disease: an overview. *Semin Arthritis Rheum* **36**, 37–49.
92. Calder PC (2006) Omega-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr* **83**, Suppl. 1505S–1519S.
93. Bagga D, Wang L, Farias-Eisner R, *et al.* (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. *Proc Natl Acad Sci U S A* **100**, 1751–1756.
94. Walters EH & Davies BH (1982) Dual effect of prostaglandin E₂ on normal airways smooth muscle *in vivo*. *Thorax* **37**, 918–922.
95. Pavord ID & Tattersfield AE (1995) Bronchoprotective role for endogenous prostaglandin E₂. *Lancet* **345**, 436–438.
96. Tilley SL, Coffman TM & Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest* **108**, 15–23.
97. Fujitani Y, Kanaoka Y, Aritake K, *et al.* (2002) Pronounced eosinophilic lung inflammation and Th2 cytokine release in

- human lipocalin-type prostaglandin D synthase transgenic mice. *J Immunol* **168**, 443–449.
98. Rajakariar R, Hilliard M, Lawrence T, *et al.* (2007) From the cover: hematopoietic prostaglandin D₂ synthase controls the onset and resolution of acute inflammation through PGD₂ and 15-deoxy Δ^{12-14} PGJ₂. *Proc Natl Acad Sci U S A* **104**, 20979–20984.
 99. Wada M, DeLong CJ, Hong YH, *et al.* (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived *versus* eicosapentaenoic acid-derived substrates and products. *J Biol Chem* **282**, 22254–22266.
 100. Tull SP, Yates CM, Maskrey BH, *et al.* (2009) Omega-3 fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. *PLoS Biol* **7**, e1000177.
 101. Chapkin RS, Akoh CC & Lewis RE (1992) Dietary fish oil modulation of *in vivo* peritoneal macrophage leukotriene production and phagocytosis. *J Nutr Biochem* **3**, 599–604.
 102. Lee TH, Hoover RL, Williams JD, *et al.* (1985) Effects of dietary enrichment with eicosapentaenoic acid and docosahexaenoic acid on *in vitro* neutrophil and monocyte leukotriene generation and neutrophil function. *N Engl J Med* **312**, 1217–1224.
 103. Sperling RI, Benincaso AI, Knoell CT, *et al.* (1993) Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. *J Clin Invest* **91**, 651–660.
 104. Katagiri YU, Kiyokawa N & Fujimoto J (2001) A role for lipid rafts in immune cell signaling. *Microbiol Immunol* **45**, 1–8.
 105. Yaqoob P (2009) The nutritional significance of lipid rafts. *Annu Rev Nutr* **29**, 257–282.
 106. Miles EA, Allen E & Calder PC (2002) *In vitro* effects of eicosanoids derived from different 20-carbon fatty acids on production of monocyte-derived cytokines in human whole blood cultures. *Cytokine* **20**, 215–223.
 107. Stulnig T, Berger M, Sigmund T, *et al.* (1998) Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-soluble membrane domains. *J Cell Biol* **143**, 637–644.
 108. Stulnig TM, Huber J, Leitinger N, *et al.* (2001) Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. *J Biol Chem* **276**, 37335–37340.
 109. Fan YY, Ly LH, Barhoumi R, *et al.* (2004) Dietary docosahexaenoic acid suppresses T cell protein kinase C ζ lipid raft recruitment and IL-2 production. *J Immunol* **173**, 6151–6160.
 110. Fan YY, McMurray DN, Ly LH, *et al.* (2003) Dietary omega-3 polyunsaturated fatty acids remodel mouse T-cell lipid rafts. *J Nutr* **133**, 1913–1920.
 111. Michaud SE & Renier G (2001) Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. *Diabetes* **50**, 660–666.
 112. Rudkowska I, Garenc C, Couture P, *et al.* (2009) Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPAR α L162V polymorphism. *Genes Nutr* **4**, 199–205.
 113. Tai ES, Corella D, Demissie S, *et al.* (2005) Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. *J Nutr* **135**, 397–403.
 114. Kirsch CM, Payan DG, Wong YS, *et al.* (1988) Effect of eicosapentaenoic acid in asthma. *Clin Allergy* **18**, 177–187.
 115. Hodge L, Salome C, Hughes J, *et al.* (1998) Effect of dietary intake of omega-3 and omega-6 fatty acids on severity of asthma in children. *Eur Respir J* **11**, 361–365.
 116. Emelyanov A, Fedoseev G, Krasnoschekova O, *et al.* (2002) Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial. *Eur Respir J* **20**, 596–600.
 117. Surette ME, Stull D & Lindemann J (2008) The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and quality of life of adult asthma patients. *Curr Med Res Opin* **24**, 559–567.
 118. McDonald CF, Vecchie L, Pierce RJ, *et al.* (1990) Effect of fish-oil derived omega-3 fatty acid supplements on asthma control. *Austral New Zealand J Med* **20**, 526.
 119. Schubert R, Kitz R, Beermann C, *et al.* (2009) Effect of omega-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge. *Int Arch Allergy Immunol* **148**, 321–329.
 120. Moreira A, Moreira P, Delgado L, *et al.* (2007) Pilot study of the effects of omega-3 polyunsaturated fatty acids on exhaled nitric oxide in patients with stable asthma. *J Investig Allergol Clin Immunol* **7**, 309–313.
 121. Arm JP, Horton CE, Mencia-Huerta JM, *et al.* (1988) Effect of dietary supplementation with fish oil lipids on mild asthma. *Thorax* **43**, 84–92.
 122. Thien FC, De Luca S, Woods RK, *et al.* (2002) Dietary marine fatty acids (fish oil) for asthma in adults and children. *The Cochrane Database of Systematic Reviews* 2002, issue 3, CD001383.
 123. Thien FC, Mencia-Huerta JM & Lee TH (1993) Dietary fish oil effects on seasonal hay fever and asthma in pollen-sensitive subjects. *Am Rev Respir Dis* **147**, 1138–1143.
 124. Nagakura T, Matsuda S, Shichijiyo K, *et al.* (2000) Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. *Eur Respir J* **16**, 861–865.
 125. Wallace FA, Miles EA, Evans C, *et al.* (2001) Dietary fatty acids influence the production of Th1- but not Th2-type cytokines. *J Leukoc Biol* **69**, 449–457.
 126. Mickleborough TD, Murray RL, Ionescu AA, *et al.* (2003) Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. *Am J Respir Crit Care Med* **168**, 1181–1189.
 127. Nathan C & Ding A (2010) Nonresolving inflammation. *Cell* **140**, 871–882.
 128. Serhan CN, Chiang N & Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol* **8**, 349–361.
 129. Serhan CN (2010) Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? *Am J Patbol* **177**, 1576–1591.
 130. Calderon Artero P, Champagne C, Garigen S, *et al.* (2012) Fish oil metabolites: translating promising findings from bench to bedside to reduce cardiovascular disease. *J Glycomics Lipidomics* **2**, 1000106.
 131. Serhan CN & Petasis NA (2011) Resolvins and protectins in inflammation resolution. *Chem Rev* **111**, 5922–5943.
 132. Serhan CN (2011) The resolution of inflammation: the devil in the flask and in the details. *FASEB J* **25**, 1441–1448.
 133. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. *Nature* **510**, 92–101.
 134. Serhan CN & Savill J (2005) Resolution of inflammation: the beginning programs the end. *Nat Immunol* **6**, 1191–1197.
 135. Levy BD (2010) Resolvins and protectins: natural pharmacophores for resolution biology. *Prostaglandins Leukot Essent Fatty Acids* **82**, 327–332.
 136. Rossi AG, Sawatzky DA, Walker A, *et al.* (2006) Cyclin-dependent kinase inhibitors enhance the resolution of



- inflammation by promoting inflammatory cell apoptosis. *Nat Med* **12**, 1056–1064.
137. Uller L, Persson CG & Erjefält JS (2006) Resolution of air way disease: removal of inflammatory cells through apoptosis, egression or both? *Trends Pharmacol Sci* **27**, 461–466.
138. Kohli P & Levy BD (2009) Resolvins and protectins: mediating solutions to inflammation. *Br J Pharmacol* **158**, 960–971.
139. Takano T, Clish CB, Gronert K, *et al.* (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A₄ and novel lipoxin B₄ stable analogues. *J Clin Invest* **101**, 819–826.
140. Takano T, Fiore S, Maddox JF, *et al.* (1997) Aspirin-triggered 15-epi-lipoxin A₄ (LXA₄) and LXA₄ stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. *J Exp Med* **185**, 1693–1704.
141. Planaguma A, Kazani S, Marigowda G, *et al.* (2008) Airway lipoxin A₄ generation and lipoxin A₄ receptor expression are decreased in severe asthma. *Am J Respir Crit Care Med* **178**, 574–582.
142. Tahan F, Saraymen R & Gumus H (2008) The role of lipoxin A₄ in exercise-induced bronchoconstriction in asthma. *J Asthma* **45**, 161–164.
143. Levy BD, Vachier I & Serhan CN (2012) Resolution of inflammation in asthma. *Clin Chest Med* **33**, 559–570.
144. Uddin M & Levy BD (2011) Resolvins: natural agonists for resolution of pulmonary inflammation. *Prog Lipid Res* **50**, 75–88.
145. Aoki H, Hisada T, Ishizuka T, *et al.* (2010) Protective effect of resolvin E1 on the development of asthmatic airway inflammation. *Biochem Biophys Res Commun* **400**, 128–133.
146. Ariel A, Fredman G, Sun YP, *et al.* (2006) Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. *Nat Immunol* **7**, 1209–1216.
147. Arita M, Bianchini F, Aliberti J, *et al.* (2005) Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med* **201**, 713–722.
148. Marcheselli VL, Hong S, Lukiw WJ, *et al.* (2003) Novel docosanoids inhibit brain ischemia–reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. *J Biol Chem* **278**, 43807–43817.
149. Gronert K (2005) Lipoxins in the eye and their role in wound healing. *Prostaglandins Leukot Essent Fatty Acids* **73**, 221–229.
150. Haworth O, Cernadas M & Levy BD (2011) NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. *J Immunol* **186**, 6129.
151. Haworth O, Cernadas M, Yang R, *et al.* (2008) Resolvin E1 regulates interleukin 23, interferon- γ and lipoxin A₄ to promote the resolution of allergic airway inflammation. *Nat Immunol* **9**, 873–879.
152. Hisada T, Ishizuka T, Aoki H, *et al.* (2009) Resolvin E1 as a novel agent for the treatment of asthma. *Expert Opin Ther Targets* **13**, 513–522.
153. Aoki H, Hisada T, Ishizuka T, *et al.* (2008) Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. *Biochem Biophys Res Commun* **367**, 509.
154. Stables MJ & Gilroy DW (2011) Old and new generation lipid mediators in acute inflammation and resolution. *Prog Lipid Res* **50**, 35–51.
155. Freedman SD, Blanco PG, Zaman MM, *et al.* (2004) Association of cystic fibrosis with abnormalities in fatty acid metabolism. *N Engl J Med* **350**, 560.
156. Hong S, Gronert K, Devchand PR, *et al.* (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. *J Biol Chem* **278**, 14677–14687.
157. Brooks DW (2009) Resolvix announced positive data from trial of resolvin RX-10045 for dry eye. Eye Doc News. <http://eyedocnews.com/002059-resolvix-announces-positive-data-from-trial-of-resolvin-rx-10045-for-dry-eye/> (accessed October 2014).
158. Duffield JS, Hong S, Vaidya VS, *et al.* (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. *J Immunol* **177**, 5902–5911.
159. Xu ZZ, Zhang L, Liu T, *et al.* (2010) Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. *Nat Med* **16**, 592–597.
160. Mickleborough TD, Vaughn CL, Shei R-J, *et al.* (2013) Marine lipid fraction PCSO-524TM (lyprinol[®]/omega XL[®]) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. *Respir Med* **107**, 1152–1163.